Affiliation:
1. Division of Nephrology, University Medicine Cluster, National University Hospital, Singapore 119074, Singapore
2. Saw Swee Hock School of Public Health, National University of Singapore, Singapore 119077, Singapore
3. Department of Pharmacy, National University Hospital, Singapore 119074, Singapore
4. Department of Laboratory Medicine, National University Hospital, Singapore 119074, Singapore
Abstract
Background: :
Drug-induced Acute Kidney Injury (AKI) develops in 10-15% of patients who receive nephrotoxic
medications. Urinary biomarkers of renal tubular dysfunction may detect nephrotoxicity early and predict
AKI.
Methods::
We prospectively studied patients who received aminoglycosides, vancomycin, amphotericin, or calcineurin
inhibitors, and collected their serial urine while on therapy. Patients who developed drug-induced AKI (fulfilling
KDIGO criteria) were matched with non-AKI controls in a 1:2 ratio. Their urine samples were batch-analyzed
at time-intervals leading up to AKI onset; the latter benchmarked against the final day of nephrotoxic therapy in non-
AKI controls. Biomarkers examined include clusterin, beta-2-microglobulin, KIM1, MCP1, cystatin-C, trefoil-factor-
3, NGAL, interleukin-18, GST-Pi, calbindin, and osteopontin; biomarkers were normalized with corresponding urine
creatinine.
Results::
Nine of 84 (11%) patients developed drug-induced AKI. Biomarkers from 7 AKI cases with pre-AKI samples
were compared with those from 14 non-AKI controls. Corresponding mean ages were 55(±17) and 52(±16)
years; baseline eGFR were 99(±21) and 101(±24) mL/min/1.73m2 (all p=NS). Most biomarker levels peaked before
the onset of AKI. Median levels of 5 biomarkers were significantly higher in AKI cases than controls at 1-3 days
before AKI onset (all µg/mmol): clusterin [58(8-411) versus 7(3-17)], beta-2-microglobulin [1632(913-3823) versus
253(61-791)], KIM1 [0.16(0.13-0.76) versus 0.07(0.05-0.15)], MCP1 [0.40(0.16-1.90) versus 0.07(0.04-0.17)], and
cystatin-C [33(27-2990) versus 11(7-19)], all p<0.05; their AUROC for AKI prediction were >0.80 (confidence
intervals >0.50), with average accuracy highest for clusterin (86%), followed by beta-2-microglobulin, cystatin-C,
MCP1, and KIM1 (57%) after cross-validation.
Conclusion: :
Serial surveillance of these biomarkers could improve the lead time for nephrotoxicity detection by
days.
Funder
National Medical Research Council, Ministry of Health Singapore
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Pharmacology
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献